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Introduction
Vaccinia virus (VV), the most studied member of the poxvirus family, is the live vaccine responsible for the successful elimination of smallpox worldwide [1] . This success has led to the development of recombinant VV as a vaccine vehicle for infectious diseases and cancer [2, 3] . This unique potency of VV is, in large part, due to its ability to elicit strong and long-lasting protective T-cell immu- [ 15, 16] . Since then, extensive studies have established a critical role for MDSCs in the regulation of T-cell responses within the tumor microenvironment [17, 18] . There are two subsets of MDSCs in mice: granulocytic MDSCs (g-MDSCs) are defined by CD11b + Ly6C lo Ly6G + ; whereas monocytic MDSCs (m-MDSCs) have a phenotype of CD11b + Ly6C hi Ly6G − [18] . It has recently become clear that these two populations have distinct cellular targets and suppressive capacities [19] . The expansion of MDSCs has also been observed in response to viral infections [20] [21] [22] [23] [24] . In a murine model of VV infection, we have recently shown that both g-MDSCs and m-MDSCs accumulated at site of infection and g-MDSCs are critical for the regulation of the NK-cell response to VV infection through the production of reactive oxygen species [23] . However, it remains unknown with regard to the role of m-MDSCs in immune responses against VV infection in vivo.
In this study, we evaluated whether m-MDSCs could influence T-cell responses to VV infection in vivo. We first showed that mMDSCs, but not g-MDSCs, from VV-infected mice could directly suppress the activation of CD4 + and CD8 + T cells in vitro. We then found that recruitment of m-MDSCs to the site of VV infection is dependent on CCR2 and that defective m-MDSC recruitment in CCR2 −/− mice led to enhanced VV-specific CD8 + T-cell response.
Furthermore, adoptive transfer of m-MDSCs into VV-infected mice significantly suppressed the VV-specific CD8 + T cells and delayed viral clearance, suggesting an important role for m-MDSCs in regulating T-cell responses against VV infection. We further demonstrated that induction of inducible nitric oxide synthase and the production of nitric oxide by m-MDSCs were required for the suppression of T-cell responses. Finally, we showed that the suppressive capacity of m-MDSC is dependent on IFN-γ.
Results

m-MDSCs inhibit T-cell proliferation in vitro
We have shown previously that g-MDSCs, but not m-MDSCs, hampered the NK-cell response to VV infection [23] . However, since both m-MDSCs and g-MDSCs accumulated in the peritoneal cavity in response to VV infection intraperitoneally, we hypothesized that m-MDSCs could regulate T-cell responses at the site of VV infection. To address this, we utilized a previously described in vitro T-cell coculture system [9] . We found that addition of m-MDSCs from VV-infected mice to T-cell cultures markedly suppressed the proliferation of both CD4 + and CD8 + T cells in response to stimulation with anti-CD3 and anti-CD28 antibodies in a cell dosedependent manner ( Fig. 1A and B) . In contrast, no T-cell suppression was observed when g-MDSCs (with g-MDSC to T-cell ratio of 2:1) were added to the culture (Fig. 1B) . Fig. 1C and D) . These results indicate that mMDSCs could directly suppress antigen-specific and -nonspecific T-cell responses in vitro.
Defective m-MDSC recruitment to infection site in CCR2 −/− mice enhances VV-specific T-cell response
It has been shown that m-MDSCs express CCR2 [25, 26] and that CCR2 −/− MDSCs had an impaired migration to the tumor microenvironment [26] . We thus used CCR2 −/− mice to evaluate the role of m-MDSCs in CD8 + T-cell response to VV infection in vivo. We first determined whether there was a defect in m-MDSC recruitment in CCR2 −/− mice in response to VV infection. We found that the percentage ( Fig. 2A and C) and absolute number ( Fig. 2B and D) of m-MDSCs in the spleen ( Fig. 2A and B) and peritoneal exudates (PEs, Fig. 2C and D) were markedly lower in VV-infected CCR2 −/− mice than the infected wild-type controls, suggesting that the migration of m-MDSCs to the site of VV infection is severely compromised. However, the recruitment of g-MDSCs was not affected (Fig. 2) . We next investigated whether defective recruitment of mMDSCs to the site of infection in CCR2 −/− mice affected the CD8 + T-cell response to VV infection. Using an immunodominant VVderived epitope peptide, B8R [20] [21] [22] [23] [24] [25] [26] [27] [27] , we assessed the production of IFN-γ by VV-specific CD8 + T cells. We found that there was a slight increase in the percentage of IFN-γ + CD8 + T cells in spleens of infected CCR2 −/− mice compared to WT mice ( Fig. 3A and B) .
However, the frequency of IFN-γ + CD8 + T cells in peritoneal cavity was significantly (p < 0.01) increased in infected CCR2 −/− mice (Fig. 3B) . Collectively, these results indicated that defective migration of m-MDSCs to the site of VV infection enhanced VV-specific CD8 T-cell response, suggesting an inhibitory role for m-MDSCs in VV-specific CD8 + T-cell response in vivo. 
m-MDSCs suppress the CD8 + T-cell response to VV infection in vivo
To further support the inhibitory role of m-MDSCs, we asked if adoptive transfer of m-MDSCs suppressed the CD8 + T-cell response to VV infection in vivo. We used a previously described model in which CD8 + T cells from Clone 4 HA-TCR transgenic mice were adoptively transferred into congenic mice, followed by infection with VV-HA [28, 29] . Five days after infection, mice were adoptively transferred with m-MDSCs purified from VV-infected mice. We found that a significant (p < 0.001) reduction in the number of total (Fig. 4A ) and IFN-γ + (Fig. 4B) 4A and B). The suppression of virus-specific T-cell response by mMDSCs was associated with an increase in VV DNA (Fig. 4C) . These results suggest that m-MDSCs can directly suppress VVspecific CD8 + T-cell response, leading to a delay in viral clearance in vivo.
m-MDSC iNOS induction and NO production in VV infection are critical for their suppressive activity
How do m-MDSCs from VV-infected mice suppress T-cell responses? The induction of iNOS and the production of NO, the induction of arginase-1 activity, and the production of ROS have been implicated in the suppressive activity mediated by MDSCs on anti-tumor T-cell responses [30] . To examine the potential roles of iNOS, arginase-1, and ROS, we added their respective inhibitors to the m-MDSC-T cell coculture system. These inhibitors include L-NMMA for iNOS, nor-NOHA for arginase-1, SOD for ROS. We found that L-NMMA could completely reverse m-MDSC-mediated suppression on the proliferation of CD4 + and CD8 + T cells, and nor-NOHA could partially reverse the suppression, whereas SOD had no effects on m-MDSC-mediated suppression (Fig. 5) . The reversal of suppression on T cells by L-NMMA was associated with a marked reduction of NO in the culture (data not shown), suggesting a role for NO in mediating the suppression. These results indicated that m-MDSC-mediated suppression on T-cell activity is mainly mediated by the induction of iNOS. We next examined whether VV infection induced m-MDSCs to upregulate iNOS and produce NO. To address this question, mice were injected with VV or LPS, i.p. Three days later, m-MDSCs or g-MDSCs were purified from peritoneal cavity exudates and assayed for iNOS induction and NO production. We found that m-MDSCs from VV-infected, but not LPS-treated, mice had a significant (p < 0.001) increase in the expression iNOS (Fig. 6A ) and production of NO (Fig. 6B ), compared to naïve control. However, no significant induction of iNOS or NO by g-MDSCs was observed (Fig. 6) . These results suggest that VV infection preferentially induced m-MDSCs to upregulate iNOS and produce NO.
IFN-γ activates m-MDSC activity
We next investigated what regulates the activity of m-MDSCs in response to VV infection. IFN-γ has been implicated in the activation of m-MDSC within the tumor microenvironment [25] . Since IFN-γ is produced in high quantity during viral infection, we hypothesized that IFN-γ may be required for the activation of m-MDSC elicited upon VV infection. To test this, we cocultured m-MDSC from peritoneal cavity with CD4 + or CD8 + T cells in the presence of a blocking anti-IFN-γ mAb. We showed that the addition of anti-IFN-γ mAb could reverse the suppression of CD4 + and CD8 + T-cell proliferation by m-MDSCs ( Fig. 7A and B) . To address the role of IFN-γ in m-MDSC activity in response to VV infection in vivo, m-MDSC purified from VV-infected WT and IFN-γ −/− mice were measured for NO production. We found that NO production by m-MDSC from IFN-γ −/− mice was significantly (p < 0.001) reduced (Fig. 7C ), compared to that from WT mice.
To further test whether IFN-γ is sufficient to induce NO production, m-MDSCs or g-MDSCs harvested bone marrow of naïve mice were cultured in the presence of IFN-γ for 24 h and assayed for the production of NO. Indeed, we found that addition of IFN-γ significantly (p < 0.001) induced the production of NO by m-MDSCs, but not g-MDSCs (Fig. 7D) . Taken together, these results support that IFN-γ is required for the suppressive capacities of m-MDSC upon VV infection.
Discussion
In this study, we showed that m-MDSCs from VV-infected mice could directly suppress the activation of CD4 + and CD8 + T cells in vitro. We also found that defective recruitment of m-MDSCs to the site of VV infection in CCR2 −/− mice enhanced VV-specific CD8 T-cell response. Furthermore, adoptive transfer of m-MDSCs into VV-infected mice significantly suppressed the activation of VV-specific CD8 T cells and delayed viral clearance, suggesting an important role for m-MDSCs in suppressing T-cell responses against VV infection. In addition, we demonstrated that m-MDSCmediated suppression on T cells was mediated by iNOS and NO, and that IFN-γ is required for the suppressive capacity of m-MDSCs. Studies have shown that VV can efficiently activate the innate immune system through both TLR-dependent and -independent pathways [6, 7] , leading to potent activation of T-cell responses to VV infection in vivo [8, 9] . VV infection can also efficiently activate NK cells [10] [11] [12] [13] [14] . Thus, VV infection is capable of activating both the innate and the adaptive immune responses for effective viral control. However, immune responses against viral infections are often tightly regulated to avoid collateral damage and systemic inflammation. We have recently shown that g-MDSCs and ROS are critical for the control of NK-cell activation in response to VV infection [23] . We now show that T-cell responses to VV infection are negatively regulated by m-MDSCs. This is mediated by the induction of iNOS and production of NO by m-MDSCs upon VV infection. ROS, iNOS/NO, and arginase-1 have been shown to mediate suppression on anti-tumor T-cell responses by MDSCs [30] . In a model of viral infection, here we show that it is m-MDSCs mediated by iNOS/NO that suppress T-cell responses, whereas gMDSCs mediated by ROS regulate the NK-cell response [23] . Interestingly, g-MDSCs even at a high dose could not suppress T-cell responses both in vitro and in vivo. The reason for the differential regulation of NK versus T-cell responses during VV infection by different MDSC subsets in vivo is not entirely unclear, but could be related to the timing for induction of suppressive capacities of MDSC subsets; the kinetics of NK-and T-cell activation; and the involvement of different signaling pathways for the respective suppression. It has been shown that NO can both directly and indirectly target T cells to modulate their activation. NO can disrupt the binding between TCR and MHC by the nitration of tyrosine residues present in the TCR-CD8 complex, leading to a reduction in T-cell responsiveness [31, 32] . Alternatively, NO can suppress IL-2R signaling, resulting in inhibition of T-cell activation and proliferation [33] . Future studies are needed to further investigate the mechanisms underlying the suppression by different subsets of MDSCs.
Our observation that migration of m-MDSCs to the site of VV infection is dependent on CCR2 is consistent with a previous report that CCR2 is required for the recruitment of immunosuppressive monocytes in response to MCMV infection [34] . However, studies have shown that migration of monocytes to the respiratory tract upon infection with modified vaccinia Ankara is related to CCR1 and CCL2 [35, 36] . The reason for the differences remains unclear, but could be related to the complexity of poxviruses that encode a series of genes responsible for various mechanisms of immune modulation.
Our results that T-cell responses to VV infection is regulated by m-MDSCs are consistent with previous observations on the role of m-MDSCs in T-cell responses in models of various tumors [25, 37, 38] , experimental autoimmune encephalomyelitis [39] , graft versus host diseases [40] , as well as other viral infections [20] [21] [22] [23] [24] . In addition, a recent report has shown that modified vaccinia Ankara-based vaccine can induce myeloid cell expansion that restricts protective CD8 T-cell immunity to SIV [41] . These observations suggest inflammatory signals that drive the activation of m-MDSCs and production of NO during viral infections are probably similar to other chronic inflammatory conditions, such as tumor microenvironment, autoimmunity, and allogeneic rejection. What could drive the production of NO by m-MDSCs in response to VV infection? Here, we provided evidence that IFN-γ produced during VV infection is critical for NO production and the suppressive function of m-MDSCs both in vitro and in vivo. It has been shown that IFN-γ is crucial for the control of viral infection and tumor growth [42] [43] [44] and IFN-γ can iNOS in a STAT1-dependent manner, leading to NO production [45, 46] . Thus, IFN-γ produced by activated T cells during VV infection could contribute to the induction of iNOS and production of NO by m-MDSCs, leading to the control of potentially overwhelming T-cell activation in vivo.
In summary, we have provided evidence that m-MDSCs can suppress T-cell responses to VV infection. Mechanistically, m-MDSC-mediated suppression on T cells is mediated by iNOS and NO, and that IFN-γ is required for the suppressive capacity of m-MDSCs. Our study may suggest potential strategies using mMDSCs to modulate T-cell activity for potential therapeutic benefits in viral infections.
Materials and methods
Mice
C57BL/6 (B6) mice were purchased from the National Cancer Institute (Frederick, MD, USA). B10.D2 and CCR2
−/− B6 mice were purchased from The Jackson Laboratory (Bar Harbor, ME, USA [48] . These mice were backcrossed onto the Thy1.1 + B10.D2 background. All mice used in this study were between 7 and 10 week of age. Experimental procedures were performed in accordance with protocols approved by the Institutional Animal Care and Use Committee of Duke University (Durham, NC, USA).
Antibodies and flow cytometry
Allophycocyanin-conjugated anti-CD11b (clone M1/70), PEconjugated anti-CD8a (clone 53-6.7), PE-Cy5-conjugated anti-CD4 (clone RM4-5), FITC-conjugated anti-IFN-γ (clone XMG1.2), PE-conjugated anti-CD90.1 (Thy1.1; clone OX-7), PE-conjugated Ly6G (clone 1A8), PE-Cy5-conjugated anti-CD8a (clone 53-6.7), FITC-conjugated Ly6C (clone AL-21), purified NA/LE anti-Mouse CD3e (clone 145-2C11), purified anti-mouse CD28 (clone 37.51), purified NA/LE anti-mouse IFN-γ (clone R4-6A2), and purified NA/LE rat IgG1κ isotype control (R3-34) were purchased from BD Biosciences (San Diego, CA, USA). FACSCanto (BD Biosciences) was used for flow cytometry event collection, which was analyzed using FACSDiva software (BD Biosciences).
Vaccinia virus
The Western Reserve strain of VV was purchased from American Type Culture Collection (Manassas, VA, USA). VV was grown in TK-143B cells (American Type Culture Collection) and purified by a 35% sucrose cushion as described [49] . The titer was determined by plaque assay on TK-143B cells, and VV was stored at −80°C until use. For in vivo studies, 2 × 10 6 PFU of live VV in 0.05 mL 1 mM Tris (pH 9) was injected into mice i.p. The recombinant VV encoding HA (VV-HA) was previously described and 5 × 10 6 PFU of live VV-HA was used for in vivo studies [50] .
In vitro T-cell proliferation and suppression assays
For antigen-specific T-cell proliferation and suppression assays, naïve clone 4 CD8 + and 6. ) generated from the BM cells as described [13] , in 300 μL T-cell media (RPMI 1640 supplemented with 5% FBS, 2 mM L-glutamine, 100 IU/mL penicillin, 100 IU/mL streptomycin, 10 mM HEPES buffer, 0.1 mM nonessentials aminoacids, 1 mM sodium pyruvate, and 50 μM 2-ME) for 72 h.
In some experiments, m-MDSCs (CD11b + Ly6G − Ly6C hi ) purified from PEs of B10.D2 mice infected with 2 × 10 6 PFU of VV for 72 h, were added to the coculture at the indicated m-MDSC:T-cell ratio.
For polyclonal proliferation assays, CD8 + T cells and CD4 + T cells were purified from naïve B10.D2 mice and labeled with CFSE as described above. CFSE-labeled T cells were then cultured in the presence of 1 μg/mL soluble anti-CD3 and 1 μg/mL soluble anti-CD28, and M-MDSCs in 300 μL T-cell media for 72 h.
In some experiments, 200 U/mL bovine superoxide dismutase (SOD; Sigma-Aldrich, St. Louis, MO, USA), 0.5 mM N Gmonomethyl-L-arginine (L-NMMA; Calbiochem, San Diego, CA, USA), or 0.5 mM N(ω)-hydroxy-nor-L-arginine (nor-NOHA; Calbiochem) were added to the coculture to inhibit ROS, iNOS, and arginase-1 activity as described [25, 51] . Finally, the biological activity of IFN-γ was blocked into the coculture by adding a final concentration of 10 μg/mL of purified anti-mouse IFN-γ or Rat IgG1κ as isotype control.
Measurement of intracellular IFN-γ production by CD8 + T cells
To measure intracellular levels of IFN-γ, 1 × 10 6 splenocytes or peritoneal cavity exudates were stimulated with either 2 μg/mL B8R 20-27 (TSYKFESV) peptide or the K d -restricted HA 518-526 (IYST-VASSL) peptide for 6 h in the presence of 5 μg/mL brefeldin A at 37°C. After incubation, cells were washed and stained with PECy5-conjugated anti-CD8 or with PE-Cy5-conjugated anti-CD8 and PE-conjugated anti-CD90.1. Cells were then permeabilized using the Cytofix/Cytoperm kit (BD Biosciences), subsequently stained with FITC-conjugated anti-IFN-γ and analyzed by flow cytometry.
In vivo suppression assay
Naïve CD8 T cells were purified from clone 4 HA-TCR transgenic mice using anti-CD8 beads according to the manufacturer's instructions (Miltenyi Biotec, Auburn, CA, USA). Cells were then washed twice in cold HBSS and resuspended at 5 × 10 4 cells/mL in HBSS. Thereafter, 1 × 10 4 CD8 + T cells were transferred intravenously into B10.D2 mice, which were subsequently infected i.p. with 5 × 10 6 PFU of VV-HA. Five days after infection, these infected mice received m-MDSCs or g-MDSCs purified from another cohort of VV-infected B10.D2 mice. Two days later, splenocytes were analyzed for total and IFN-γ + clonotypic T cells by intracellular cytokine staining.
Measurement of VV DNA
Total genomic DNA was isolated from the spleen. Real-time quantitative PCR was used to measure VV genomic DNA using primers located in the VV A33R gene. The sequences of the forward and reverse primers for A33R were 5'-TATTACTGACGCCGC TGTTG-3' and 5'-GTGTTGATGATTCCGCAGTG-3', respectively. Amounts of VV DNA were normalized to β-actin gene within each sample. Normalized viral DNA value in each sample was calculated as the relative quantity of VV DNA divided by the relative quantity of β-actin gene.
iNOS expression by real-time PCR
Total RNA was isolated from 2 × 10 5 sorted m-MDSCs and g-MDSCs using RNAeasy Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer. First-strand cDNA was performed using RT kit (Promega, Madison, WI, USA). Quantitative PCR was carried out with primers for iNOS and relative amounts of iNOS mRNA were normalized to β-actin. The sequences of the forward and reverse primers for iNOS were GTTCTCAGCCCAA-CAATACAAGA and GTGGACGGGTC GATGTCAC, respectively.
NO production
Equal volumes of culture supernatants (50 μL) and Greiss reagent (1% sulfanilamide in 5% phosphoric acid and 0.1% N-1-naphthyl-ethylenediamine dihydrochloride in double-distilled water, Sigma-Aldrich) were mixed together. After 10 min incubation at room temperature, the absorbance at 550 nm was measured using microplate plate reader (Bioteck Instrument, Winooski, VT, USA). Nitrite (NO) concentrations were determined by comparing the absorbance values for the test samples to a standard curve generated by serial dilution of 0.25 mM sodium nitrite [51] .
Statistical analysis
A two-sided, unpaired Student t-test with 95% confidence bound and Welch's correction was used for all statistical analysis, which was performed using GraphPad Prism Version 5.0f for Mac OS X (GraphPad Software, San Diego, CA, USA). Significance was assumed at p < 0.05.
